Raloxifene enhances vertebral mechanical properties independent of bone density

Matthew Allen, Ken Iwata, Masahiko Sato, David Burr

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Anti-remodeling agents produce similar reductions in vertebral fracture risk despite large differences in BMD changes suggesting the mechanism of fracture risk reduction may differ among these agents. Forty-eight intact (non-ovariectomized) skeletally mature female beagle dogs were treated orally for 12 months with clinically relevant doses of risedronate (RIS, 0.10 mg/kg/day), alendronate (ALN, 0.2 mg/kg/day), raloxifene (RAL, 0.50 mg/kg/day), or saline (VEH, 1 ml/kg/day). After sacrifice, the following measurements were made on vertebral bone: areal (aBMD) and volumetric (vBMD) bone mineral densities, tissue mineralization by ash content, static and dynamic histomorphometric parameters, microdamage, and extrinsic and intrinsic measures of biomechanical strength, stiffness and energy to fracture. At these doses, RAL suppressed bone turnover (-20%) significantly less than the bisphosphonates (-66 and -71%) and did not produce significant differences in aBMD, vBMD, BV/TV or percent ash compared to VEH-treated animals. Microdamage accumulation in RAL-treated animals was not significantly different than VEH; both RIS and ALN had significantly higher crack surface density compared to VEH. Stiffness was significantly higher than VEH in all treatment groups. Ultimate load divided by aBMD, a measure of strength independent of BMD, was significantly higher only in RAL-treated animals compared to VEH (+16%, P = 0.015). Based on these data, we conclude that raloxifene produces improvements in bone mechanical properties in ways that do not involve increases in BMD.

Original languageEnglish
Pages (from-to)1130-1135
Number of pages6
JournalBone
Volume39
Issue number5
DOIs
StatePublished - Nov 2006

Fingerprint

Bone Density
Bone and Bones
Alendronate
Fracture Fixation
Bone Remodeling
Diphosphonates
Risk Reduction Behavior
Dogs
Raloxifene Hydrochloride
Therapeutics
Risedronate Sodium

Keywords

  • Biomechanics
  • Bisphosphonates
  • Microdamage
  • Osteoporosis
  • SERMS

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Raloxifene enhances vertebral mechanical properties independent of bone density. / Allen, Matthew; Iwata, Ken; Sato, Masahiko; Burr, David.

In: Bone, Vol. 39, No. 5, 11.2006, p. 1130-1135.

Research output: Contribution to journalArticle

Allen, Matthew ; Iwata, Ken ; Sato, Masahiko ; Burr, David. / Raloxifene enhances vertebral mechanical properties independent of bone density. In: Bone. 2006 ; Vol. 39, No. 5. pp. 1130-1135.
@article{37aa386d351d4c9fb365aa6941512379,
title = "Raloxifene enhances vertebral mechanical properties independent of bone density",
abstract = "Anti-remodeling agents produce similar reductions in vertebral fracture risk despite large differences in BMD changes suggesting the mechanism of fracture risk reduction may differ among these agents. Forty-eight intact (non-ovariectomized) skeletally mature female beagle dogs were treated orally for 12 months with clinically relevant doses of risedronate (RIS, 0.10 mg/kg/day), alendronate (ALN, 0.2 mg/kg/day), raloxifene (RAL, 0.50 mg/kg/day), or saline (VEH, 1 ml/kg/day). After sacrifice, the following measurements were made on vertebral bone: areal (aBMD) and volumetric (vBMD) bone mineral densities, tissue mineralization by ash content, static and dynamic histomorphometric parameters, microdamage, and extrinsic and intrinsic measures of biomechanical strength, stiffness and energy to fracture. At these doses, RAL suppressed bone turnover (-20{\%}) significantly less than the bisphosphonates (-66 and -71{\%}) and did not produce significant differences in aBMD, vBMD, BV/TV or percent ash compared to VEH-treated animals. Microdamage accumulation in RAL-treated animals was not significantly different than VEH; both RIS and ALN had significantly higher crack surface density compared to VEH. Stiffness was significantly higher than VEH in all treatment groups. Ultimate load divided by aBMD, a measure of strength independent of BMD, was significantly higher only in RAL-treated animals compared to VEH (+16{\%}, P = 0.015). Based on these data, we conclude that raloxifene produces improvements in bone mechanical properties in ways that do not involve increases in BMD.",
keywords = "Biomechanics, Bisphosphonates, Microdamage, Osteoporosis, SERMS",
author = "Matthew Allen and Ken Iwata and Masahiko Sato and David Burr",
year = "2006",
month = "11",
doi = "10.1016/j.bone.2006.05.007",
language = "English",
volume = "39",
pages = "1130--1135",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Raloxifene enhances vertebral mechanical properties independent of bone density

AU - Allen, Matthew

AU - Iwata, Ken

AU - Sato, Masahiko

AU - Burr, David

PY - 2006/11

Y1 - 2006/11

N2 - Anti-remodeling agents produce similar reductions in vertebral fracture risk despite large differences in BMD changes suggesting the mechanism of fracture risk reduction may differ among these agents. Forty-eight intact (non-ovariectomized) skeletally mature female beagle dogs were treated orally for 12 months with clinically relevant doses of risedronate (RIS, 0.10 mg/kg/day), alendronate (ALN, 0.2 mg/kg/day), raloxifene (RAL, 0.50 mg/kg/day), or saline (VEH, 1 ml/kg/day). After sacrifice, the following measurements were made on vertebral bone: areal (aBMD) and volumetric (vBMD) bone mineral densities, tissue mineralization by ash content, static and dynamic histomorphometric parameters, microdamage, and extrinsic and intrinsic measures of biomechanical strength, stiffness and energy to fracture. At these doses, RAL suppressed bone turnover (-20%) significantly less than the bisphosphonates (-66 and -71%) and did not produce significant differences in aBMD, vBMD, BV/TV or percent ash compared to VEH-treated animals. Microdamage accumulation in RAL-treated animals was not significantly different than VEH; both RIS and ALN had significantly higher crack surface density compared to VEH. Stiffness was significantly higher than VEH in all treatment groups. Ultimate load divided by aBMD, a measure of strength independent of BMD, was significantly higher only in RAL-treated animals compared to VEH (+16%, P = 0.015). Based on these data, we conclude that raloxifene produces improvements in bone mechanical properties in ways that do not involve increases in BMD.

AB - Anti-remodeling agents produce similar reductions in vertebral fracture risk despite large differences in BMD changes suggesting the mechanism of fracture risk reduction may differ among these agents. Forty-eight intact (non-ovariectomized) skeletally mature female beagle dogs were treated orally for 12 months with clinically relevant doses of risedronate (RIS, 0.10 mg/kg/day), alendronate (ALN, 0.2 mg/kg/day), raloxifene (RAL, 0.50 mg/kg/day), or saline (VEH, 1 ml/kg/day). After sacrifice, the following measurements were made on vertebral bone: areal (aBMD) and volumetric (vBMD) bone mineral densities, tissue mineralization by ash content, static and dynamic histomorphometric parameters, microdamage, and extrinsic and intrinsic measures of biomechanical strength, stiffness and energy to fracture. At these doses, RAL suppressed bone turnover (-20%) significantly less than the bisphosphonates (-66 and -71%) and did not produce significant differences in aBMD, vBMD, BV/TV or percent ash compared to VEH-treated animals. Microdamage accumulation in RAL-treated animals was not significantly different than VEH; both RIS and ALN had significantly higher crack surface density compared to VEH. Stiffness was significantly higher than VEH in all treatment groups. Ultimate load divided by aBMD, a measure of strength independent of BMD, was significantly higher only in RAL-treated animals compared to VEH (+16%, P = 0.015). Based on these data, we conclude that raloxifene produces improvements in bone mechanical properties in ways that do not involve increases in BMD.

KW - Biomechanics

KW - Bisphosphonates

KW - Microdamage

KW - Osteoporosis

KW - SERMS

UR - http://www.scopus.com/inward/record.url?scp=33749537051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749537051&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2006.05.007

DO - 10.1016/j.bone.2006.05.007

M3 - Article

VL - 39

SP - 1130

EP - 1135

JO - Bone

JF - Bone

SN - 8756-3282

IS - 5

ER -